The Conversation (0)
Novan (Nasdaq:NOVN) announced an update on the SB414 nitric oxide-releasing cream product candidate and its application to two therapeutic indications: atopic dermatitis and psoriasis. As quoted in the press release: Based on results of two complementary Phase 1b clinical trials with SB414 in patients with psoriasis and atopic dermatitis, Novan intends to advance the development …
Novan (Nasdaq:NOVN) announced an update on the SB414 nitric oxide-releasing cream product candidate and its application to two therapeutic indications: atopic dermatitis and psoriasis.
As quoted in the press release:
Based on results of two complementary Phase 1b clinical trials with SB414 in patients with psoriasis and atopic dermatitis, Novan intends to advance the development of SB414 as a treatment for atopic dermatitis and conduct additional exploratory trials in psoriasis and acne rosacea.
The purpose of the two randomized, double-blind, vehicle-controlled Phase 1b trials was to assess target engagement through a reduction of key inflammatory biomarkers and to evaluate the systemic exposure of SB414. The trials were also designed to measure the safety, tolerability and initial efficacy endpoints of SB414 in patients.